Kornimate/medical-research-clean huggingface dataset:
three-dimensional fluoroscopic guidance during transbronchial cryobiopsy

Conditions: Lung Carcinoma

Summary: this study assesses the effectiveness of transbronchial cryobiopsy guided by 3-dimensional fluoroscopy. transbronchial cryobiopsy is a procedure to collect lung tissue. the main side effect seen after a transbronchial cryobiopsy is pneumothorax (air leaking out of the lung, which may cause a completely or partially collapsed lung). the standard imaging scans used during this procedure are 2-dimensional (like a photo), which can make it difficult for the doctor to know exactly where the biopsy tool is during the procedure. if the exact location of the device is not clear, a patient can be at a higher risk of pneumothorax. using a 3-dimensional imaging technique may help to decrease the risk of pneumothorax during transbronchial cryobiopsy.

primary objective: i. to determine if transbronchial cryobiopsy guided by three-dimensional fluoroscopy reduces the incidence of pneumothorax up to 72 hours after transbronchial cryobiopsy. secondary objective: i. to describe outcomes of cryobiopsy, need for interventions related to transbronchial cryobiopsy, radiation dose, and any complications or adverse events after transbronchial cryobiopsy guided by three-dimensional fluoroscopy. outline: patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. patients' medical records are also reviewed.

Eligibility criteria:
inclusion criteria: * age 18 years or older * presence of an intraparenchymal lung lesion for which cryobiopsy is deemed the most appropriate method of biopsy * ability to provide informed consent exclusion criteria: * acute respiratory failure (defined as oxygen requirement \> 4 l/min by nasal cannula above baseline, or need for any intervention to support ventilation and/or gas exchange for any duration, including invasive and non-invasive positive pressure ventilation, high-flow therapy, non-rebreather mask, or venturi mask) * intensive care unit (icu) admission * forced vital capacity (fvc) \< 50% or diffusing capacity of the lung for carbon monoxide (co) (dlco) \< 35% (if pulmonary function tests are available) * known or suspected pulmonary hypertension (defined as elevated right ventricular systolic pressure on echocardiogram, if available) * acute renal failure or chronic kidney disease * platelets \< 100,000/ul * international normalized ratio (inr) \> 1.5 * use of anticoagulant therapy that cannot be held for 2 days * use of antiplatelet therapy (other than baby aspirin) that cannot be held for 5 days * any bleeding diathesis * pregnancy
high altitude residents with high altitude pulmonary hypertension (haph), 6mwt assessed at high altitude (3200m) vs low altitude (760m)

Conditions: High Altitude Pulmonary Hypertension

Summary: to study the effect of relocation from 3200m (aksay) to 760m (bishkek) in highlanders with high altitude pulmonary hypertension (haph) who permanently live \>2500m on 6-minute walk distance (6mwd)

this research in highlanders with haph diagnosed by echocardiography and defined by a rv/ra \>30 mmhg who permanently live at ha \>2500 m will perform a 6-minute walk distance test near their living altitude in aksay at 3200 m and on day 2 and 7 at 760 m after relocation

Eligibility criteria:
inclusion criteria: * permanently living \>2500 m * haph diagnosed with a minimum rv/ra of 30 mmhg assessed by echocardiography at an altitude of 3200 m * written informed consent exclusion criteria: * highlanders who cannot follow the study investigations, * patients with moderate to severe concomitant lung disease (fev1\ 20 cigarettes/day or \>20 pack-years. * coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Keywords: pulmonary hypertension hypoxia high altitude 6-minute walk test
efficacy and safety of roxadustat for treatment of anemia in participants with lower risk myelodysplastic syndrome with low red blood cell transfusion burden

Conditions: Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts); Anemia

Summary: the purpose of this study is to determine whether fg-4592 is safe and effective in the treatment of anemia in participants with lower risk mds and low red blood cell transfusion burden.

this study includes an open-label lead in, a double-blind component, and an open-label high erythropoietin component. there is a screening period of up to 42 days followed by a treatment period of 52 weeks and a 4-week end of treatment assessment.

Eligibility criteria:
key inclusion criteria: * diagnosis of primary mds classified by the international prognostic scoring system - revised (ipss-r) as very low, low or intermediate risk with \<5% bone marrow blasts. there is no minimum time from diagnosis to registration/randomization except to allow for proper ipss-r classification to be made (within 16 weeks prior to randomization), and to show transfusion dependence for participants in both portions of the study. * rbc transfusion of either 2-4 prbc units during the 8 weeks prior to registration/randomization or 1 prbc in two consecutive periods of 8 weeks within the 16 weeks prior to registration/randomization. open-label lead-in participants only, the requirement to demonstrate transfusion dependence can also be met by a principal investigator starting this particular participant on prbc transfusion during the screening period. * no restriction on prior use of recombinant erythropoietins or analogues (erythropoiesis-stimulating agents \[esas\]), except no esa use within 8 weeks prior to day 1 registration/randomization. * hemoglobin (hb) ≤10.0 grams/deciliter (g/dl) during screening * eastern cooperative oncology group (ecog) of 0-2 at screening key exclusion criteria: * diagnosis of secondary mds associated with prior chemotherapy, extensive radiation therapy (\>25% of bone marrow reserve), and or/other significant chemical or radiation exposure * significant myelofibrosis (\>2+ fibrosis) * mds associated with 5q(del) cytogenetic abnormality * screen serum erythropoietin level \> 400 milli-international units (miu)/milliliter (ml) • clinically significant anemia, as determined by the investigator, due to non-mds etiologies such as iron deficiency, vitamin b12 or folate deficiency, autoimmune or hereditary hemolysis or anemia or hemorrhage or hereditary anemia such as sickle cell anemia or thalassemia.

Keywords: myelodysplastic syndromes anemia hemoglobin (hb) low risk myelodysplastic syndrome low risk mds
turmeric effect on reduction of serum prolactin and related hormonal change and adenoma size in prolactinoma patients

Conditions: Hyperprolactinoma

Summary: prolactinoma is the most prevalent anterior hypophysis tumor. the principal treatment for this disorder is dopamine agonist drugs including bromocriptin and cabergoline. however, 50% of bromocriptin treated and 17% of cabergoline treated patients are resistant to these drugs. curcumin is the main derivative of turmeric ,an old spice which is used frequently in indian and iranian cuisine. it has been proved that curcumin can reduce mammotrope cells proliferation and also intracellular hormone production. the purpose of this study is to evaluate the effect of turmeric on prolactinoma patients.


Eligibility criteria:
inclusion criteria: * hyperprolactinemia * microprolactinoma exclusion criteria: * pregnancy * macroadenoma * neurologic signs due to tumor

Keywords: hyperprolactinoma turmeric amenorrhea
simple and evidence-based examination and treatment of shoulder pain in general practice

Conditions: Shoulder Pain; Frozen Shoulder; Rotator Cuff Tendinosis; Myalgia; Rotator Cuff Impingement Syndrome; Rotator Cuff Tear or Rupture, Not Specified as Traumatic

Summary: previous research suggests that general practitioners find handling patients with shoulder pain difficult and that the current care for shoulder pain is not in line with the best available evidence (1).this project aims to assess the effectiveness, costs and implementation of an evidence-based guideline for shoulder pain in general practice.

a simplified and evidence-based algorithm for examination and treatment of patients with shoulder pain will be developed and implemented in general practice. the purpose is to improve quality of care and provide gps with a simplified and efficient tool to handle patients with common shoulder- related pain. the study is a stepped-wedge, cluster-randomized trial with a hybrid design including a effectiveness, cost and implementation assessment of a guideline-based intervention in clinical practice (2). general practitioners in norway will be recruited and the gp offices will be randomized to the time of crossover from current treatment as usual (tau) to the implementation of the intervention. the intervention is a tailored strategy that includes workshops for general practitioners covering information and access to a decision support tool, an education program where the general practitioner learn an evidence-based approach to shoulder pain and access to patient information materials. outcomes will be measured at patient and gp levels, using self-report questionnaires, focus group interviews and register based data.

Eligibility criteria:
inclusion criteria: * pain in the shoulder region * above 18 years exclusion criteria: * unable to fill in self-report questionnaires or do not understand norwegian * acute injury with clinical suspicion of fracture, luxation of shoulder joints or large tendon ruptures * clinical suspicion of referred pain to the shoulder area from other organs * signs of inflammatory joint disease * suspicion of malignant disease * symptoms and signs of cervical radiculopathy

Keywords: general practice implementation guideline
low laser therapy on facial motor functions function and synkinesis in patients with bell's palsy

Conditions: Bell's Palsy

Summary: to determine the effects of low-level laser therapy on facial motor functions and synkinesis in patients with bell's palsy

a randomised controlled trial tested low-level laser therapy (lllt) for bell's palsy. lahore's ittefaq hospital selected 32 bell's palsy patients for the research. the facial disability index (fdi), house-brackmann scale (hbs), and sunnybrook facial grading system were used to collect data over ten months (sfg). lllt and conventional therapy were randomly assigned to two groups. spss 25 compared pre- and post-treatment values of the two groups.

Eligibility criteria:
inclusion criteria: * male female diagnosed with idiopathic bell's palsy by physician * age 30-60years * bell's palsy in patients having known history of hypertension * bell's palsy in patients having known history of diabetes exclusion criteria: * participants with a middle ear infection * parotid gland tumor * malignant otitis external * tumors in the base of the lateral skull * upper motor neuron facial palsy * segmental muscle weakness * and recurrent episodes of facial paralysis, polyneuropathies
get living: graded exposure treatment for children and adolescents with chronic pain

Conditions: Chronic Pain; Neuralgia; Musculoskeletal Pain; Headache

Summary: the broad aim of the study is to implement and evaluate the efficacy of graded exposure treatment (get living) to target elevated pain-related fears in children with chronic pain. pain-related fear is an important psychological factor associated with poor outcomes in children suffering with chronic pain. to examine the efficacy of get living in addressing pain-related fears the investigators propose to use a sequential replicated randomized single-case experimental phase design with multiple measures. the specific aims are to 1) evaluate the effectiveness and acceptability of individually tailored get living for children with high pain-related fear and functional disability and 2) define anatomical and resting state connectivity patterns in the brains of children and adolescents with complex chronic pain prior to and after participation in get living.


Eligibility criteria:
inclusion criteria: * pain-related fear (score \>40 on the fear of pain questionnaire (fopq (simons et al., 2011a)) * musculoskeletal, neuropathic limb or back pain, or headache * functional limitations (score \> 12 on the functional disability inventory (fdi (kashikar-zuck et al., 2001; walker and greene, 1991)). exclusion criteria: * significant cognitive impairment (e.g., intellectual disability) * serious psychopathology (e.g., active suicidality). * acute trauma (e.g., spondylolithesis, disk herniation, fracture, acute tendonitis) * systemic disease in active inflammatory state * biomechanical deficit that would limit ability to engage in exposure activities (e.g. severe muscle atrophy) * making gains in current physical therapy or have not had physical therapy, but it is clearly indicated
functional study to indentify genetic etiology of rare diseases - origin

Conditions: Rare Diseases; Genetic Disease

Summary: next generation sequencing (ngs) allows some better diagnostic results, particularly, in the rare diseases field. at a twenty five percent rate, those exams highlight some variants which are not yet described in human pathology. the relationship between a variant found inside a candidate gene and a pathology, is able to be confirmed by functional studies at a protein level. this study aims to build a biological collection to feed further functional studies to confirm the relationship between ngs identified variants, and the clinical signs and symptoms.


Eligibility criteria:
inclusion criteria: patient : * child or adult affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood. * patient included inside the bamara (french rare disease national data bank) database dedicated to the rare diseases. * patient affiliated to the french social security system. * patient consent form or legal representative consent form obtained. patient's parent : * parent of a patient affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood. * parent included in the bamara database. * parent affiliated to the french social security system. * parent consent form obtained for himself/herself. patient's brother or sister : * brother or sister of a patient (underage or adult) affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood. * brother or sister included in the bamara database. * brother or sister affiliated to the french social security system. * brother or sister consent form obtained for themselves or from their legal representative. exclusion criteria: * poor understanding of the french language * legal of administrative liberty deprivation * psychiatric force care
pilot study of an advance care planning intervention among persons with dementia

Conditions: Advanced Care Planning; Dementia

Summary: advance care planning allows people to have their wishes taken into account even in the advanced stages of the persons' condition and at the end of life when the person may be unable to communicate. however, a recent review found an absence of high-quality guidelines for advanced care planning in dementia care. since few evidence-based resources exist, the investigators propose a study to generate, refine, and pilot test an education information sheet designed to promote advanced care planning among families of persons with dementia.

to determine the feasibility, acceptability and preliminary efficacy of an education information sheet to promote advance care planning among family members of persons with advanced dementia in long-term services and support facilities. introducing an education information sheet containing prognosis and outcomes will be feasible, acceptable, and increase self-efficacy and do-not-hospitalize decision preferences among family members of persons with advanced dementia.

Eligibility criteria:
inclusion criteria: * family member of a person with a diagnosis of dementia (any type) * english-speaking family member * family member of a person with dementia admitted to a nursing home exclusion criteria: * inability to understand/read english * advance directive already in patient chart
erdafitinib in metastatic steroid-cell ovarian cancer

Conditions: Ovarian Cancer; Steroid Cell Tumor, Malignant

Summary: this is a single participant study of erdafitinib for the treatment of a patient with metastatic steroid-cell tumor of the ovary.

erdafitinib was approved by fda in 2019 for patients with locally advanced or metastatic urothelial carcinoma with susceptible fgfr alterations. blocking the fgf/fgfr signaling axis by tyrosine kinase inhibitors was proved to be a successful therapeutic strategy in numerous tumor types. erdafitinib was the first approved fgfr-tki for treating metastatic urothelial carcinoma based on remarkable results of the phase ii trial (blc2001), that enrolled 212 patients of whom 101 patients was treated with uptitration dose of 9mg daily. the median follow-up for efficacy was 24 months (iqr 22.7\*26.6). the objective response rate was 40% (95% ci) of 101 patients of uptitration group. the common grade 3-4 adverse events were stomatitis and hyponatremia4. a phase iii trial (nct03390504) is being performed to compare the efficacy of erdafitinib versus vinflunine or docetaxel or pembrolizumab in advanced urothelial cancer. multiple clinical trials are being conducted on the effectiveness of erdafitinib in a variety of cancers that harbors fgfr alterations. these indicate the potential to improve control in this rare disease which otherwise is devastating and associated with a very high likelihood of recurrence and poor survival.

Eligibility criteria:
inclusion criteria \& exclusion criteria: this is a single patient study and the protocol was specifically designed for this single patient. this patient case was discussed in the hospital expert molecular tumor board rounds consisting of representatives from specialist genomic profiling and gynecologic medical oncology departments. the discussion surrounded the best next therapeutic option in this extremely rare cancer subtype without clear standard of care guidelines. the recommendation from this discussion was to perform radiation therapy to her bone lesion and access target treatment against fgfr4 amplification, such as erdafitinib that is a pan fgfr kinase inhibitor and binds to and inhibits fgfr1, fgfr2, fgfr3, and fgfr4 enzyme activity.
deferoxamine in the treatment of aneurysmal subarachnoid hemorrhage (asah)

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: aneurysmal subarachnoid hemorrhage (asah) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.the initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. deferoxamine mesylate (dfo), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals. this trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of asah for patients that are admitted to the hospital at the university of michigan or peking university health science center. eligible participants will be enrolled and randomized to 1 of 2 doses of deferoxamine or placebo (saline). information regarding the patients will be collected and followed for up to 6 months post discharge.


Eligibility criteria:
inclusion criteria: * aneurysmal sah confirmed with vascular imaging * aneurysm treated with endovascular or microsurgical intervention * hunt-hess ≤ 4 * modified fisher grade i-iv * glasgow coma scale (gcs) ≥ 7 following external ventricular drain (evd) placement if indicated * first dose of drug can be administered within 24 hours of symptom onset * functional independence prior to sah, modified rankin scale (mrs) ≤ 1 * informed consent obtained by patient or legal authorized representative (lar) exclusion criteria: * previous hypersensitivity to or treatment with deferoxamine * presence of giant aneurysm (\>25 mm in size) * known severe iron deficiency anemia, hemoglobin (hgb) g/dl ≤ 7 or transfusion dependent * irreversibly impaired brainstem function * abnormal renal function, serum creatinine\> 2 mg/dl * pre-existing severe disability, mrs ≥ 2 * coagulopathy, including use of anti-platelet or anticoagulant drugs * known severe hearing loss * patients with significant respiratory disease such as chronic obstructive pulmonary disease, pulmonary fibrosis, or on home oxygen (o2) * taking iron supplements containing \> 325 mg of ferrous iron * pregnancy * life expectancy less than 90 days due to co-morbidities * concurrent participation in another research protocol for investigation of another experimental therapy, though observational studies are allowed * prior history of hepatic dysfunction * known cytopenia (platelets \< 50,000, absolute neutrophil count \< 500)

Keywords: deferoxamine placebo
a study to evaluate the safety and tolerance of syhx1903 in patients with relapsed/refractory hematologic malignancies

Conditions: Acute Myeloid Leukemia; Lymphoma; Multiple Myeloma

Summary: this trial is an open-label, multi-center, dose escalation, dose expansion, and cohort expansion phase i/ii clinical study of syhx1903 in patients with relapsed/refractory hematologic malignancies. this trial aims to evaluate the safety, tolerance, pharmacokinetics, and preliminary antitumor activity of syhx1903 in patients with relapsed/refractory hematologic malignancies.


Eligibility criteria:
inclusion criteria: * diagnosis of relapsed/refractory hematologic malignancies confirmed by the world health organization (who) criteria. * eastern cooperative oncology group (ecog) score ≤ 1. * life expectancy ≥ 3 months. exclusion criteria: * pregnant and lactating females. * proven hematologic malignancies of the central nervous system. * diagnosed acute promyelocytic leukemia (predominantly granulocytic promyelocytes in bone marrow, which are ≥ 30% in nec). * history of other malignant tumors within 5 years, except for cured skin basal cell carcinoma, skin squamous cell carcinoma or cervical carcinoma in situ.